Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients

Bone Marrow Transplantation

Volumn 18, Issue SUPPL. 3, 1996, Pages

  Chanock, S J ^a   Walsh, T J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antifungal therapy; Immunocompromised host; Mycosis; Supportive care

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; CLOTRIMAZOLE; CORTICOSTEROID; CYCLOSPORIN A; FLUCONAZOLE; FLUCYTOSINE; GROWTH FACTOR; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; PARACETAMOL; PYRROLE DERIVATIVE; TERFENADINE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG TOXICITY; FEVER; GASTROINTESTINAL SYMPTOM; HEART ARREST; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; MYCOSIS; NEUTROPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PATIENT CARE; PRIORITY JOURNAL; RIGOR; RISK; TORSADE DES POINTES; UREMIA;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL TRIALS; FLUCONAZOLE; FLUCYTOSINE; HUMANS; IMIDAZOLES; IMMUNOCOMPROMISED HOST; ITRACONAZOLE; MYCOSES; NEUTROPENIA; TRANSPLANTATION CONDITIONING; TRIAZOLES;

EID: 0030457524     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. Meyers J. Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17: S10-S17.
2. Walter E, Bowden R. Infection in the bone marrow transplant recipient. Infect Dis Clin N Am 1995; 9: 823-847.
3. Hiemenz J, Greene J. Special considerations for the patient undergoing allogeneic or autologous bone marrow transplantation. Hem/Onc Clin N Am 1993; 7: 961-1002.
4. Milliken S, Powle R. Antifungal prophylaxis in bone marrow transplantation. Rev Infect Dis 1990; 12: S374-S379.
5. Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 1992; 14: S120-S126.
6. Berenguer J, Allende M, Lee J et al. Pathogenesis of pulmonary aspergillosis: granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Resp Crit Care Med 1995; 152: 1079-1086.
7. Goodrich J, Reed E, Mori M et al. Clinical features and analysis of risk factor for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164: 731-740.
8. McWhinney P, Kibbler C, Hamon M et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation. Clin Infect Dis 1994; 17: 397-405.
9. Morrison V, Haake R, Weisdorf D. Non-candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1994; 96: 497-507.
10. Bodey G. The emergence of fungi as major hospital pathogens. J Hosp Infect 1988; 11: 411-426.
11. Walsh T, Lee J. Prevention of invasive fungal infections in patients with neoplastic disease. Clin Infect Dis 1993; 17 (Suppl. 2): S468-S480,
12. Walsh T, Hiemenz J, Pizzo P. Evolving risk factors for invasive fungal infections: all neutropenic patients are not the same. Clin Infect Dis 1994; 18: 793-798.
13. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1994; 12: 2471-2508.
14. Chanock S, Friefeld A. The use of cytokines in fever and neutropenia. Int J Pediatr Hematol/Oncol 1995; 2: 173-183.
15. Chanock S. Evolving risk factors for infectious complications of cancer therapy. In: Pizzo PA (ed.). Infectious Complications in the Immunocompromised Host. WB Saunders: Philadelphia, PA, 1993, pp 771-794.
16. Lecciones JA, Lee JW, Navarro EE et al. Vascular catheterassociated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis J 1992; 14: 875-883.
17. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-111.
18. Walsh TJ, Lee J, Lecciones J et al. Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 1991; 13: 496-503.
19. Rousey S, Russler S, Gottlieb M, Ash R Low-dose amphotericin B prophylaxis against invasive aspergillus infections in allogeneic marrow recipients. Am J Med 1991; 91: 484-492.
20. Perfect J, Klotman M, Gilbert C et al. Prophylactic intravenous amphotericin B in neutropenic autologous marrow transplant recipients. J Infect Dis 1992; 165: 891-897.
21. Walsh T, Gonzalez C, Lyman C et al. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv Pediatr Infect Dis 1995; 11: 187-290.
22. Stein R, Alexander J. Sodium protects against nephrotoxicity in patients receiving amphotericin B. Am J Med Sci 1989; 98: 299-308.
23. Lopez-Bernstein G, Bodey G, Fainstein V et al. Treatment of systemic fungal infection with liposomal amphotericin B. Arch Intern Med 1989; 149: 2533-2536.
24. Ringden O, Meunier F, Tollemar J et al. Efficacy of amphotericin B encapsulated in liposomes (Ambisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28: 73-81.
25. Ringden O, Tollemar J. Liposomal amphotericin B (Ambisome) treatment of invasive fungal infection in immunocompromised children. Mycoses 1993; 36: 187-194.
26. Tollemar J, Anderson ??, Ringdon O et al. A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (Ambisome) and conventional amphotericin B in transplant recipients. Mycoses 1992; 35: 215-223.
27. Conneally E, Cafferkey M, Daly P et al. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 1990; 5: 403-406.
28. Jeffery G, Beard M, Ikram R et al. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am J Med 1991; 90: 685-692.
29. Meunier-Carpentier F, Snoeck R, Gerain J et al. Amphotericin B nasal spray as prophylaxis against aspergillosis in patients with neutropenia. New Engl J Med 1984; 311: 1056-1057.
30. Hertenstein B, Kern W, Schmeiser T et al. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol 1994; 68: 21-26.
31. Cushing D, Bustamante C, Devlin A et al. Aspergillus infection prophylaxis: Amphotericin B-nose spray, a double-blind trial. Proc Abstr 31st Intersci Conf Antimicrob Agents Chemother, 1991, p 222 (Abstr. 737).
32. Ezdinli E, O'Sullivan D, Wasser L et al. Oral amphotericin B for candidiasis in patients with hematologic neoplasms. An autopsy study. J Am Med Assoc 1979; 242: 258-260.
33. Owens N, Nightingale C, Schweizer R et al. Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med 1984; 144: 290-293.
34. Wingard J, Vaughn W, Braine H et al. Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 1987; 83: 1103-1110.
35. Walsh T, Lee J, Aoki S et al. Experimental basis for usage of fluconazole for prevention or early treatment of disseminated candidiasis in granulocytopenic hosts. Rev Infect Dis 1990; 12: S307-S317.
36. Goodman J, Winston D, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992; 326: 845-851.
37. Slavin M, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
38. Wingard J, Merz W, Rinaldi M et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New Engl J Med 1991; 325: 1274-1277.
39. Persons D, Laughlin M, Tanner D et al. Fluconazole and Candida krusei fungemia. New Engl J Med 1991; 325: 1315-1316.
40. Sangeorzan J, Bradley S, He X et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97: 339-346.
41. Alangaden G, Chandrasekar P, Bailey E, Khaliq Y. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. Bone Marrow Transplant 1994; 14: 919-924.
42. Ellis M, Clink H, Ernst P et al. Controlled study of fluconazole in the prevention of fungal infection in neutropenic patients with hematologic malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994; 13: 3-11.
43. Wingard J, Merz W, Rinaldi M et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37: 1847-1849.
44. Lee JW, Seibel NL, Amantea M et al. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 1992; 120: 987-993.
45. Rex J, Bennett J, Sugar A et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. New Engl J Med 1994; 331: 1325-1330.
46. Anaissie E, Bodey G, Kantarjian H et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991; 91: 142-150.
47. Saag M, Powderly W, Cloud G et al. Treatment of acute ADIS-associated cryptococcal meningitis with amphotericin B or fluconazole: results of a randomized clinical trial. New Engl J Med 1992; 326: 83-89.
48. Denning D, Lee J, Hosteller J et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135-144.
49. De Beule K, De Doncker P, Cauwenbergh G et al. The treatment of apergillosis and aspergilloma with itraconazole: clinical results of an open international study (1982-1987). Mycoses 1988; 31: 476-483.
50. Berenguer J, Ali N, Allende M et al. Itraconazole in experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole plasma concentrations. Antimicrob Agents Chemother 1994; 38: 1303-1308.
51. Kreissel W, Kochling G, Schilling CV et al. Therapy of invasive aspergillosis with itraconazole: improvement of therapeutic efficacy of early diagnosis. Mycoses 1991; 34: 385-391.
52. Tricot G, Joosten E, Boogaerts M et al. Ketaconazole versus itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two non-randomized studies. Rev Infect Dis 1987; 9: S94-S99.
53. Francis P, Walsh T. Evolving role of flucytosinc in immunocompromised patients: new insights into safety, pharmacokinetic, and antifungal therapy. Clin Infect Dis 1992; 15: 1003-1018.